Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

Explore clinical trials studying Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound. Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study

Refine in advanced search Browse all conditions

Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound trial results

Recruiting

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

NCT07219459

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +11 more
Locations: USC Norris Comprehensive Cancer Center Los Angeles, California, United States

Peidmont Healthcare, Inc Atlanta, Georgia, United States

OSF St. Francis Medical Center Peoria, Illinois, United States

Hannover Medical School Hanover, Lower Saxony, Germany

View all 14 locations

View Trial Details

Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound trial results

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Related conditions